Loading clinical trials...
Loading clinical trials...
This is a multicenter, open-label extension (OLE), single-arm study designed to assess the long-term safety and tolerability of oral IKT-001 administered once daily.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Inhibikase Therapeutics
NCT07120789 · Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), and more
NCT07457762 · Pulmonary Arterial Hypertension (PAH)
NCT01347216 · Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
NCT06941441 · Pulmonary Arterial Hypertension (PAH), Exercise Therapy
NCT06865118 · Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH), and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions